Potassium iodide by age after iodine release

It is six in the morning when the cell phones in a house a few kilometers from a nuclear plant ring at the same time. Civil defense reports that there was a reactor failure, that radioactive iodine may be released, and that residents should stay indoors, close the windows and wait for guidance on potassium iodide tablets. Five people live in the house: the father, 45 years old; the mother, 38 years old, who is breastfeeding; a three-week-old baby; a 6-year-old daughter; and a 15-year-old son who weighs 55 kg. The grandmother, 72 years old, lives with them and is being treated for a multinodular goiter and heart disease. In the kitchen drawer there is a box of 65 mg tablets that the city distributed years ago. The mother calls the health unit and asks who should take them, how much and for how long. The scene is fictional and was written for teaching.

This text uses the scenario as a setting for clinical reasoning for students and health professionals. The topic is thyroid blocking with stable iodine after a release of radioactive iodine. The focus is what the professional decides on the phone or at the distribution point: who benefits most, what the dose is for each age, when to take it, when not to repeat it and who should not take it. It does not replace guidance from the health authority or your country's emergency plan. If you play the case of the day in NEXO, you will recognize the challenge: deciding with clues that arrive in sequence.

Key points

• Potassium iodide protects only the thyroid and only against radioactive iodine, and it does not replace sheltering or evacuation.
• Children, pregnant women and breastfeeding women are the groups with the most benefit, and above age 40 the benefit is smaller.
• The daily dose ranges from 16 mg in the newborn to 130 mg in the adult, according to FDA guidance.
• Protection is greatest when the tablet is taken shortly before or soon after exposure begins.
• Newborns, pregnant women and breastfeeding women should avoid repeated doses, and the newborn needs monitoring of thyroid function.
• Iodine allergy, dermatitis herpetiformis, hypocomplementemic vasculitis and nodular thyroid disease with heart disease are contraindications in the package insert.

Why this is a reasoning scenario

The mother's phone call seems simple, but it brings together decisions that the professional rarely makes. The question is not whether potassium iodide works, but for whom it is worthwhile, at what dose and at what moment. The answer changes with each person's age in the house, with pregnancy and breastfeeding, with thyroid disease and with the time that has passed since the release. The most common error is to treat the family as a block and give everyone the same dose, or to fail to give it to the baby out of fear of the effect on the newborn.

Potassium iodide is a thyroid-blocking medication indicated only in a nuclear emergency with release of radioactive iodine (ThyroSafe package insert). It should be taken only when public authorities instruct (ThyroSafe package insert). The package insert notes that it protects only the thyroid and should be used together with the other protective measures indicated by the authorities (ThyroSafe package insert). That sentence already settles part of the phone conversation: the tablet is not a shield against radiation in general.

The post on clinical decision-making helps organize the choice by group, and the post on diagnostic uncertainty shows how to act when the estimated dose is not yet available.

What the scene teaches

The scene trains six habits. The first is to remember that the tablet is a complement to sheltering and evacuation. The second is to separate the family by age and by condition before talking about dose. The third is to give priority to the baby, the children, the teenager and the mother who is breastfeeding. The fourth is to recognize that the grandmother has a contraindication described in the package insert. The fifth is to explain the time window and the rule of one dose every 24 hours. The sixth is to plan monitoring of the newborn's thyroid function.

What is not at stake

The text does not address acute radiation syndrome or internal contamination with cesium, which were the topics of earlier texts in this series. It also does not address external decontamination or the treatment of thyroid cancer. The focus is the decision about stable iodine in the first hours and first days. The post about diagnostic pause helps avoid closing the conversation before asking who is pregnant, who is breastfeeding and who has thyroid disease.

How radioactive iodine reaches the thyroid

In a reactor accident, iodine-131 is among the most important short-lived radionuclides released into the atmosphere, along with tellurium-132 and iodine-133 (Willems et al., 2022). After Chernobyl, the thyroid dose in most exposed people came mainly from iodine-131 (Willems et al., 2022). The material can be inhaled or swallowed and reach the thyroid (ThyroSafe package insert). The package insert explains that the damage probably only appears years later and that children are the most susceptible to it (ThyroSafe package insert).

The thyroid needs iodine to produce the hormones T4 and T3 (Calcaterra et al., 2022). It does not distinguish stable iodine from radioactive iodine, and so the strategy is to saturate the gland with ordinary iodine before the radioactive iodine arrives (Aaseth et al., 2019). With the gland saturated with non-radioactive iodide, the uptake of iodine-131 becomes minimal (Aaseth et al., 2019). The package insert describes the same reasoning in plain language: the thyroid can only store a certain amount of iodine, and potassium iodide blocks or reduces the entry of radioactive iodine (ThyroSafe package insert).

Willems et al. sum up the effect in numbers. In adults with a normal thyroid, 100 mg to 200 mg of iodide taken shortly before exposure blocks at least 95 percent of the thyroid dose (Willems et al., 2022). REMM records that, when iodide is taken within 1 to 2 hours of inhalation, it blocks more than 90 percent of uptake (REMM, potassium iodide). The numbers show why timing weighs so heavily in the decision, as will be seen below.

Two mechanisms that add up

The model by Rump et al. describes the protection as the sum of two effects: competition for the transporter on the cell membrane and the Wolff-Chaikoff effect, in which excess iodine slows hormone production (Rump et al., 2022). In the model, the dose that gives half the protection throughout pregnancy is around 1.5 mg (Rump et al., 2022). The calculation shows that the tablet dose is more than enough to block the gland, and that doubling the dose adds no protection.

What the tablet does not do

Potassium iodide does not protect against cesium, against external radiation from the cloud or against material deposited on the ground. It protects only the thyroid against the uptake of radioactive iodine (ThyroSafe package insert). The review by Saenko and Mitsutake notes that, in external exposure, measures follow the principle of keeping the dose as low as reasonably possible, while blocking with stable iodine may be indicated in addition to other measures when exposure to radioactive iodine is expected (Saenko and Mitsutake, 2024). That is why the guidance to stay home with the windows closed still applies even after the family has taken the tablet.

Who has the most to lose: age, pregnancy and lactation

The Chernobyl experience is the basis for deciding by age. The 2001 FDA guidance records that the increase in thyroid cancer began about four years after the accident (FDA, 2001 guidance). The excess was 30 to 60 times higher in children who were 0 to 4 years old at the time (FDA, 2001 guidance). The same guidance notes that the risk increases from a thyroid dose of 5 cGy in children (FDA, 2001 guidance).

The review by Saenko and Mitsutake shows that many of the thyroid cancers occurred in people who were 0 to 5 years old at the Chernobyl accident, while none occurred in that age range after Fukushima (Saenko and Mitsutake, 2024). The authors note that doses in Fukushima were much lower than those in Chernobyl and that an increase in thyroid cancer caused by radiation is unlikely (Saenko and Mitsutake, 2024). They also describe that the Chernobyl tumors changed over time, became less aggressive and shifted from gene fusions to point mutations as the main alteration (Saenko and Mitsutake, 2024).

Iodine deficiency in the diet

A lack of iodine in food also matters. Populations with dietary iodine deficiency are more vulnerable to radioactive iodine exposure and may have more unwanted effects with high doses of stable iodine (Willems et al., 2022). In the case-control study from Belarus and Russia, stable iodine deficiency, measured by the iodine content of the soil, appears among the risk factors adjusted for dose (Saenko and Mitsutake, 2024). The question about diet does not change the tablet dose, but it helps explain why some regions had more cases than others.

Over 40 years old

For the 45-year-old father, the answer is different. Willems et al. explain that people over 40 benefit less because the risk of thyroid cancer from internal exposure is very small compared with that of children and young adults, and because older people may have more side effects (Willems et al., 2022). In the FDA table, an adult over 40 should only take the tablet if the projected thyroid dose exceeds 500 cGy (FDA, 2001 guidance). That dose is high and is not usually the situation of a family sheltering at home, but the decision belongs to the authority that estimates the dose.

Pregnancy and breastfeeding

A pregnant woman deserves double attention because iodine crosses to the fetus. In the model by Rump et al., without blocking, the dose to the mother's thyroid increases by about 45 percent in the first weeks of pregnancy and stays in that range until term (Rump et al., 2022). From the 12th week, the dose to the fetal thyroid grows more than the mother's and reaches three times the maternal dose at term (Rump et al., 2022). Protection of the mother and the fetus increases together with the amount of stable iodine given to the mother at the time of exposure (Rump et al., 2022).

The FDA places pregnant and breastfeeding women in the group with an indication from a projected dose of 5 cGy, with a dose of 130 mg (FDA, 2001 guidance). The mother in the scene is breastfeeding, so she falls into this group. The package insert asks pregnant women, breastfeeding women and babies under one month to take the indicated dose and see a doctor as soon as possible (ThyroSafe package insert). The same insert recommends avoiding repeated doses in these groups (ThyroSafe package insert).

The newborn

The three-week-old baby gains the most and requires the most care. The ThyroSafe package insert notes that babies under one month have a higher risk of hypothyroidism after iodide (ThyroSafe package insert). It recommends checking thyroid function in babies under one month who took the medication (ThyroSafe package insert). The FDA guidance calls for monitoring TSH and free T4 in the newborn (FDA, 2001 guidance). Calcaterra et al. recall that hypothyroidism during brain development can leave intellectual disability (Calcaterra et al., 2022). The conclusion is not to skip the tablet, but to give a dose and ensure the test afterward.

Doses by age: the table the family needs

The table in the 2001 FDA guidance is the reference for doses by age (FDA, 2001 guidance). The ThyroSafe and iOSAT package inserts present the same ranges in language for the public (ThyroSafe package insert) (iOSAT package insert). The table below combines the two sources. The threshold column shows the projected thyroid dose from which the FDA indicates the tablet (FDA, 2001 guidance).

Group	Projected thyroid dose threshold (FDA)	Daily dose of potassium iodide	65 mg tablets
Adult over 40 years old	over 500 cGy	130 mg	2
Adult 18 to 40 years old	10 cGy or more	130 mg	2
Pregnant or breastfeeding	5 cGy or more	130 mg	2
Adolescent 12 to 18 years old	5 cGy or more	65 mg (130 mg if adult-sized)	1 or 2
Child aged 3 to 12 years	5 cGy or more	65 mg	1
Child aged 1 month to 3 years	5 cGy or more	32 mg	half a tablet
Newborn up to 1 month	5 cGy or more	16 mg	a quarter of a tablet

The package insert indicates 2 tablets per day, or 130 mg, for adults over 18 years (ThyroSafe package insert). For adolescents aged 12 to 18 years, weight defines the dose: with at least 150 pounds, about 68 kg, it is 2 tablets, and below that it is 1 tablet (ThyroSafe package insert). The FDA guidance uses a similar cutoff, of 70 kg, for the adolescent approaching adult size (FDA, 2001 guidance). The 15-year-old son in the scene weighs 55 kg, so he takes 65 mg.

The 6-year-old daughter is in the 3 to 12 years range and takes 1 tablet, or 65 mg (ThyroSafe package insert). The three-week-old baby is in the birth to 1 month range and takes 16.25 mg (ThyroSafe package insert). The mother, who is breastfeeding, takes 130 mg (FDA, 2001 guidance). The father, aged 45, would only take it if the authority estimated a dose above 500 cGy (FDA, 2001 guidance).

How to prepare the child's dose

The package insert explains how to prepare a liquid mixture for those who cannot swallow the tablet (ThyroSafe package insert). The steps begin by placing a 65 mg tablet in a small bowl and crushing it into a fine powder with the back of a metal spoon (ThyroSafe package insert). Then 4 teaspoons of water are added and mixed until the powder dissolves, and this solution is mixed with 4 teaspoons of milk, orange juice, flat soda, raspberry syrup or infant formula (ThyroSafe package insert). The newborn receives 2 teaspoons, the child aged 1 month to 3 years receives 4 teaspoons and the child aged 3 to 12 years receives 8 teaspoons (ThyroSafe package insert). The mixture can stay in the refrigerator for up to 7 days, and what is left over must be thrown away (ThyroSafe package insert).

The mixture has 8.125 mg of iodide per teaspoon (ThyroSafe package insert). The package insert warns that the measure is in teaspoons, not tablespoons (ThyroSafe package insert). The REMM also lists the doses of the 65 mg/mL oral solution: 2 mL, 1 mL, 0.5 mL and 0.25 mL, depending on the range (REMM, potassium iodide). In practice, the professional should check which product the family has before giving the measure.

What national policies do with the table

In the WHO survey of 2016 and 2017, 36 countries responded and all used potassium iodide in the tablets (Willems and colleagues, 2022). Tablets of 130 mg were used by about a quarter of them, 28 percent (Willems and colleagues, 2022). A pediatric formulation, liquid or gel, existed in 10 countries, and 21 countries, 58 percent, did not use a pediatric formulation (Willems and colleagues, 2022). Only 12 countries had an age limit above which blocking is not recommended, eight of them with a cutoff at 40 years (Willems and colleagues, 2022). Most countries did not use an age limit (Willems and colleagues, 2022).

Time window and duration of protection

Timing decides much of the protection. According to the REMM, iodide taken within 1 to 2 hours of inhalation blocks more than 90 percent of uptake, the effect is much smaller after 4 hours and even smaller after 12 hours (REMM, potassium iodide). The FDA guidance notes that iodide still has an important protective effect when taken 3 or 4 hours after exposure (FDA, 2001 guidance). In the WHO survey, all countries recommended taking it shortly before or shortly after the start of exposure (Willems and colleagues, 2022).

The package insert advises taking the tablet as soon as the authorities instruct (ThyroSafe package insert). That is why the tablet at home, distributed in advance, makes a difference: the family does not need to go out to get the medicine at the moment when it should be sheltered. Matsunaga and colleagues recall that Japan distributes stable iodine in advance to residents near the plants, but that the number of residents who actually received the tablets is still limited (Matsunaga and colleagues, 2021).

One dose every 24 hours

The protection from one dose lasts about 24 hours, which is why the FDA recommends one dose per day for as long as the risk lasts (FDA, 2001 guidance). The package insert says that if a repeat is needed, the second dose should be taken 24 hours after the first, and not sooner (ThyroSafe package insert). It also says that taking more than one dose per day does not help and increases the chance of side effects (ThyroSafe package insert). The authorities state how many days to take it, and use should continue until the risk of significant exposure by inhalation or ingestion ends (ThyroSafe package insert).

In the WHO survey, countries that planned for repeat dosing gave the second dose after 24 hours, with exceptions: at most one dose for newborns and at most one or two for pregnant and breastfeeding women (Willems et al., 2022). In the scene, if the release continues the next day, the authority may recommend a new dose for the daughter and the son, but the baby and the mother need medical assessment first (ThyroSafe package insert).

When the exposure is through food

Not every exposure comes through the air. The FDA guidance cites inhalation of contaminated air and ingestion of contaminated food and drink as the routes of exposure, and places food and milk control alongside evacuation and sheltering (FDA, 2001 guidance). When the route is food, the main measure is to avoid the contaminated food, not to extend the tablet for weeks. The package insert notes that iodide should not be taken for longer than indicated (ThyroSafe package insert).

Risks and reasoning errors

The most common errors in this decision are errors of reasoning, not of pharmacology. They appear when the hurry of the emergency replaces the question about each person in the household.

• Thinking the tablet protects against all radiation and leaving home to get more, when it protects only the thyroid {TSL}.
• Giving the same dose to everyone, without adjusting for the teenager's age and weight {TSL}.
• Failing to give it to the newborn for fear of hypothyroidism, when the guidance is to give one dose and check thyroid function {TSL}.
• Repeating the dose before 24 hours or doubling the dose, which does not increase protection and increases side effects {TSL}.
• Forgetting the grandmother's contraindication with nodular goiter and heart disease {TSL}.
• Taking the tablet without an order from the authority, or too late, when protection is already small {REM}.

Contraindications and precautions

The package insert says that iodide should not be taken by anyone with iodine allergy, dermatitis herpetiformis, hypocomplementemic vasculitis or nodular thyroid disease with heart disease (ThyroSafe package insert). The grandmother in the scene has multinodular goiter and heart disease, so she should not take it (ThyroSafe package insert). The iOSAT package insert lists the same contraindications (iOSAT package insert). People with other thyroid diseases may take it, but should see a doctor if they need more than a few days of use (ThyroSafe package insert). The FDA guidance also lists Graves' disease and autoimmune thyroiditis among the conditions that call for caution (FDA, 2001 guidance).

Side effects

According to the package insert, short-term use at the recommended dose is safe (ThyroSafe package insert). Possible effects include swelling of the salivary glands, nausea, vomiting, diarrhea, stomach pain, fever, headache, metallic taste and allergic reactions (ThyroSafe package insert). In rare cases, iodide can cause hyperthyroidism, hypothyroidism or thyroid enlargement (ThyroSafe package insert). Aaseth et al. note that use without need can reveal or worsen hyperthyroidism and hypothyroidism and even cause permanent thyroid disease (Aaseth et al., 2019). Calcaterra et al. also warn about prolonged and inappropriate use of stable iodine (Calcaterra et al., 2022).

The experience of Poland

Poland distributed stable iodine after Chernobyl to 10.5 million children and 7 million adults (FDA, 2001 guidance). The FDA guidance records transient hypothyroidism in 0.37 percent of treated newborns, 12 of 3214, with no sequelae reported up to then (FDA, 2001 guidance). Gastrointestinal effects reached 2 percent and skin rash about 1 percent (FDA, 2001 guidance). There were two allergic reactions, in adults with known iodine sensitivity (FDA, 2001 guidance). These numbers help the professional explain to the mother that the risk of the tablet is small compared with the risk of radioactive iodine for the baby.

Communication with the family

Fear of side effects weighs on adherence. In the study by Matsunaga and colleagues, with 247 guardians of children aged 0 to 6 near the Genkai plant, the main reasons for not receiving stable iodine were anxiety about side effects, 40.2 percent, and distrust of efficacy, 23.5 percent (Matsunaga and colleagues, 2021). Living up to 5 km from the plant and knowing that children have priority in blocking were associated with receiving the tablets (Matsunaga and colleagues, 2021). The authors conclude that it is necessary to know the guardians' risk perception and adapt communication (Matsunaga and colleagues, 2021).

Whitcomb and colleagues describe the United States response to Fukushima and cite the use and availability of potassium iodide among the challenges faced by the Centers for Disease Control and Prevention (Whitcomb and colleagues, 2015). They also report that translating technical information for people who were not radiation specialists took time and left room for calculation errors (Whitcomb and colleagues, 2015). The mother's phone call is exactly that point of translation.

Regulatory situation: FDA, WHO and national policies

The ThyroSafe package insert lists 65 mg tablets in packs of 10 and 20 units (ThyroSafe package insert). The iOSAT package insert lists the same active ingredient and the same dose table by age (iOSAT package insert). The REMM lists the products approved by the FDA up to December 2016: iOSAT in 130 mg and 65 mg tablets, ThyroSafe in 65 mg tablets, the ThyroShield solution and a solution from Mission Pharmacal (REMM, potassium iodide).

The 2001 FDA guidance defined the projected dose thresholds and the doses by age used to this day in package inserts (FDA, 2001 guidance). It records that the WHO, in 1999, used a threshold of 1 cGy for people up to 18 years old and for pregnant and breastfeeding women (FDA, 2001 guidance). After Chernobyl, the WHO published the first guidelines on stable iodine in 1989 (Willems and colleagues, 2022). In 2015, the IAEA general safety requirements, part 7, updated the guidance on blocking (Willems and colleagues, 2022). In 2017, the WHO published the revised guideline on iodine thyroid blocking for planning and response to radiological and nuclear emergencies (Willems and colleagues, 2022).

What changes between countries

The WHO survey shows the variation. In half of the countries that responded, the tablets were treated as a medicine (Willems and colleagues, 2022). In 20 countries, they were offered to the public without a prescription and free of charge (Willems and colleagues, 2022). The distribution policy was very specific to each country and sometimes changed between regions of the same country (Willems and colleagues, 2022). One country used an intervention level of 100 mSv of thyroid dose for children up to 18 years old and 1000 mSv for adults aged 18 to 40 (Willems and colleagues, 2022). For the professional, the lesson is to know the local plan before the emergency, because it defines who receives and when.

How NEXO helps train this reasoning

NEXO publishes one fictional clinical case per day, with up to six progressive clues. You can attempt the diagnosis at each clue, searching for the code in ICD-10, and you receive proximity feedback at five levels. The format trains the same skill as this scene: putting together data that arrive gradually and deciding without closing too early. The post on case-based learning explains why this format works, and the post on differential diagnosis shows how to keep hypotheses open.

Three exercises with cases

• Redo the scene changing the father's age to 35 years and decide whether the approach changes.
• Redo the scene with a pregnant woman at 20 weeks in place of the breastfeeding mother and explain what happens to the fetal thyroid.
• Redo the scene assuming the release continues for three days and say who can repeat the dose and who needs a doctor first.

Teachers and content creators can build their own cases in the space for Creators. The exercise works well in the classroom, in emergency simulations and in training for primary care teams near nuclear plants.

Frequently asked questions

Does potassium iodide protect against all radiation?

No. It only protects the thyroid against the uptake of radioactive iodine (ThyroSafe package insert).

What is the adult dose?

130 mg per day, or 2 tablets of 65 mg, for adults over 18 years (ThyroSafe package insert).

Can I give it to a newborn?

Yes, 16.25 mg per day, and thyroid function should be checked afterwards (ThyroSafe package insert).

How long does the tablet protect?

About 24 hours, so the dose is daily for as long as the risk lasts (FDA, 2001 guidance).

Who should not take it?

People with iodine allergy, dermatitis herpetiformis, hypocomplementemic vasculitis or nodular thyroid disease with heart disease (ThyroSafe package insert).

Final checklist

• I remembered that the tablet complements sheltering and does not replace it.
• I sorted the family by age, weight, pregnancy and lactation.
• I gave priority to the baby, the children, the teenager and the mother.
• I checked each person's dose in the table and the product the family has.
• I asked about iodine allergy and about thyroid disease with heart disease.
• I explained the rule of one dose every 24 hours and the order from the authorities.
• I planned the TSH and free T4 monitoring for the newborn.
• I advised the mother to see a doctor before repeating the dose.

Want to practice reasoning with progressive clues? Play the case of the day.

References

1. Aaseth J, Nurchi VM, Andersen O. Medical Therapy of Patients Contaminated with Radioactive Cesium or Iodine. Biomolecules. 2019. PMID 31835766.
2. BTG International Inc. ThyroSafe (potassium iodide tablets, USP, 65 mg). Package insert on DailyMed, revised on 03/2026. Accessed on 24/10/2026. Official source.
3. Anbex Inc. IOSAT (potassium iodide tablets, USP, 65 mg). Package insert on DailyMed. Accessed on 24/10/2026. Official source.
4. Calcaterra V, Mameli C, Rossi V, et al. The Iodine Rush: Over- or Under-Iodination Risk in the Prophylactic Use of Iodine for Thyroid Blocking in the Event of a Nuclear Disaster. Front Endocrinol (Lausanne). 2022. PMID 35692388.
5. Food and Drug Administration. Guidance: Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies. December 2001. Official source.
6. Matsunaga H, Orita M, Taira Y, Takamura N. Risk perception of the pre-distribution of stable iodine to guardians of children living around the Genkai Nuclear Power Plant, Saga Prefecture, Japan. PLoS One. 2021. PMID 33983948.
7. Radiation Emergency Medical Management. Potassium Iodide (KI). Accessed on 24/10/2026. Official source.
8. Rump A, Hermann C, Lamkowski A, et al. Simulations of radioiodine exposure and protective thyroid blocking in a new biokinetic model of the mother-fetus unit at different pregnancy ages. Arch Toxicol. 2022. PMID 35922584.
9. Saenko V, Mitsutake N. Radiation-Related Thyroid Cancer. Endocr Rev. 2024. PMID 37450579.
10. Whitcomb RC Jr, Ansari AJ, Buzzell JJ, et al. A public health perspective on the U.S. response to the Fukushima radiological emergency. Health Phys. 2015. PMID 25627948.
11. Willems P, Carr Z, Dreger S, et al. Survey on national practices regarding iodine thyroid blocking in 2016-2017. Environ Adv. 2022. PMID 35782592.